Targeted RAS Drug Shows Survival Benefit Across Advanced Pancreatic Cancer Subgroups

A new subgroup analysis of the phase 3 RASolute 302 trial indicates that the targeted therapy daraxonrasib improved survival compared with standard chemotherapy in patients with previously treated metastatic pancreatic cancer, and that the benefit held consistently across different RAS mutation types, chemotherapy comparison regimens and prior treatment settings. The findings were presented at the European Society for Medical Oncology (ESMO) Congress by Dr. Zev Wainberg, professor of medicine and investigator at the UCLA Health Jonsson Comprehensive Cancer Center.

The analysis builds on earlier results from RASolute 302, which showed that patients with metastatic pancreatic cancer who had received prior treatment and were assigned daraxonrasib lived a median of 13.2 months, compared with 6.7 months for those receiving standard chemotherapy. The newly reported analyses were designed to determine whether that survival advantage was confined to particular molecular subsets or treatment comparisons, or whether it extended across the broader trial population, a question with direct consequences for how the drug may be used in clinical practice.

Pancreatic cancer remains one of the most difficult malignancies to treat, especially once it has spread to other organs and progressed after initial therapy. More than 90 percent of pancreatic cancers carry mutations in RAS genes, which normally help regulate cell growth. When mutated, these genes can send continuous growth-promoting signals that drive cancer development. In the trial, researchers collected detailed molecular information across all RAS mutation subsets, which they describe as one of the largest detailed molecular analyses conducted in metastatic pancreatic cancer. Daraxonrasib is an oral targeted therapy designed to block multiple forms of the active RAS protein, including both mutated and nonmutated forms. Unlike agents that inhibit a single genetic mutation, this multi-target approach may be active across a broader range of pancreatic tumors.

The phase 3 trial enrolled approximately 500 patients with metastatic pancreatic cancer who had already received treatment. Participants were randomly assigned to receive either daraxonrasib, taken as a once-daily pill, or one of several standard chemotherapy regimens. The new analyses examined whether survival differed according to the specific RAS mutation found in a patient’s tumor, the chemotherapy regimen used for comparison, and the setting in which patients had received earlier treatment. Across the RAS mutation groups examined, survival outcomes consistently favored daraxonrasib over chemotherapy, including among patients whose tumors had no identified RAS mutation. The benefit was likewise consistent across the different chemotherapy comparison groups, suggesting the drug’s effectiveness was not dependent on being measured against one particular regimen.

“This update represents the largest analysis of any RAS inhibitor across all RAS mutation subgroups. In this analysis, we demonstrate that depending on the individual mutation, daraxonrasib may have a different response,” said Wainberg. “These data have important implications for planning the next wave of RAS targeted therapies with the ultimate goal of completely replacing chemotherapy.”

The drug, marketed as RASONQUE and manufactured by Revolution Medicines, received approval from the U.S. Food and Drug Administration in August 2026 for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy. The researchers note important limitations. Some patient subgroups in the additional analyses were small, and further follow-up will be needed to clarify long-term benefits across different populations. Because the reported results are subgroup and consistency analyses of a trial in previously treated metastatic disease, they do not address use of the drug in earlier treatment settings.

Subject of Research: Subgroup analyses of a phase 3 trial of the RAS inhibitor daraxonrasib in previously treated metastatic pancreatic cancer

Article Title: ESMO: New analysis reinforces survival benefits of targeted therapy for advanced pancreatic cancer

Article References: ESMO: New analysis reinforces survival benefits of targeted therapy for advanced pancreatic cancer. Original publication (Bibliographic details unavailable.)

Image Credits: AI Generated

DOI: Not provided

Keywords: pancreatic cancer, daraxonrasib, RAS mutations, RASolute 302, ESMO Congress, targeted therapy, phase 3 trial, metastatic cancer, chemotherapy, UCLA Health, Revolution Medicines, survival analysis